AiCure and OncoBay Clinical Provide AI to Oncology Trials
AiCure and OncoBay Clinical have announced a partnership to provide oncology sponsors with scalable, AI-powered insights. A subsidiary of the Moffitt Cancer Center, OncoBay will make AiCure's proprietary AI platform available for oncology trials, aiming to provide sponsors and sites with a more holistic understanding of patient health and site optimization.
The oncology drug pipeline has grown by 63% since 2013, but the average success rate of oncology drugs is only 3.4%. To address this discrepancy and the unique challenges of oncology trials, particularly given the complex treatment regimens, AiCure and OncoBay aim to improve patient support and trial retention, while also providing sponsors and sites with greater visibility into patient behavior. Through AiCure's patient engagement solution, Patient Connect, oncology sites can remotely monitor patients and use real-time communication tools to guide them through treatment protocols, including which medication to take and when, as well as allow direct access to a clinician.
To learn more, click here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
